NeuroSense Therapeutics (NRSN) Long-Term Deferred Tax (2021 - 2023)

NeuroSense Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $3.3 million in Q4 2023.

• Quarterly Long-Term Deferred Tax rose 101.03% year-over-year to $3.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.3 million (up 101.03% YoY) and the FY2023 annual result came in at $3.3 million, up 101.03% from the prior year.
• Long-Term Deferred Tax grew to $3.3 million in Q4 2023 per NRSN's latest filing, from $1.6 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $3.3 million in Q4 2023 and troughed at $953000.0 in Q4 2021.
• A 3-year average of $2.0 million and a median of $1.6 million in 2022 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax jumped 73.03% in 2022, then jumped 101.03% in 2023.
• Over 3 years, Long-Term Deferred Tax stood at $953000.0 in 2021, then surged by 73.03% to $1.6 million in 2022, then surged by 101.03% to $3.3 million in 2023.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.3 million, $1.6 million, and $953000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.